Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 532660 | NSE Symbol : VIVIMEDLAB | ISIN : INE526G01021 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
01-Aug-2025	13-Aug-2025	Quarterly Results	Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve (1) Un-audited Financial Results (Standalone & Consolidated) of the company for the quarter ended 30th June 2025 (2) Board Report (3) AGM for FY2025 & related matters. (4) Proposal for raising of funds Further we would like to inform that pursuant to the SEBI (Prohibition of Insider Trading) Regulations the company has intimated its Designated Persons including Directors regarding the closure of trading window from 01.07.2025 to till 48 hours after the declaration of un-audited Financial Results (Standalone & Consolidated) of the company for the quarter ended 30th June 2025 Kindly take the above information on records.
13-May-2025	30-May-2025	Accounts	Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve Notice of Board Meeting / Closure of Trading Window Outcome of Board Meeting (As Per BSE Announcement Dated on 31.05.2025)
30-Jan-2025	14-Feb-2025	Quarterly Results	VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 further to our letter dated 26.12.2024 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on 14th day of February 2025 at Hyderabad inter alia to consider and approve un-audited Financial Results (Standalone & Consolidated) of the company for the Quarter and nine months ended December 31 2024. Further we would like to inform that pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the company has intimated its Designated Persons including Directors regarding the closure of trading window from 01.01.2025 to till 48 hours after the declaration of un-audited Financial Results (Standalone & Consolidated) of the company for the Quarter and nine months ended December 31 2024. Q3 Results FY2025 (As Per Bse Announcement Dated on 14.02.2025)
06-Jan-2025	10-Jan-2025	Quarterly Results	VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/01/2025 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 10th Day of January 2025 at Hyderabad inter alia to consider and approve un-audited Financial Results (Standalone & Consolidated) of the company for the quarter and half year ending 30th September 2024 any other items. ResultsQ1FY2025 (As Per BSE Announcement Dated on: 11/01/2025)
11-Dec-2024	11-Dec-2024	Change in Directors	Attached
07-Nov-2024	14-Nov-2024	Accounts	VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 further to our letter dated 06.09.2024 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday14th Day of November 2024 at Hyderabad inter alia to consider and approve (1) audited Financial Results (Standalone & Consolidated) of the company for the quarter and year ended 31st March 2024 (2) Board Report (3) AGM for FY2024 & related matters.
23-Aug-2024	06-Sep-2024	Accounts	VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/09/2024 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 further to our letters dated 19.03.2024 & 17.05.2024 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 06th Day of September 2024 at Hyderabad inter alia to consider and approve (1) audited Financial Results (Standalone & Consolidated) of the company for the quarter and year ended 31st March 2024 (2) Board Report (3) AGM for FY2024 & related matters. Further we would like to inform that pursuant to the SEBI (Prohibition of Insider Trading) Regulations the company has intimated its Designated Persons including Directors regarding the closure of trading window from 01.04.2024 to till 48 hours after the declaration of audited Financial Results (Standalone & Consolidated) of the company for the quarter and year ended 31st March 2024. The Board of Directors of the Company at its meeting held on September 06, 2024 inter alia, have approved / resolved/ taken note of the following: 1. Deferment for declaring the audited financial results for the FY 2024, owing to paucity of time for completing the Audit as the new statutory auditors M/s. SVRL & Co. have been appointed in the EGM held on 14.08.2024 2. To file an application to the office of the Registrar of Companies, Bangalore, Karnataka, seeking an extension of time by three months for the convening of AGM for the Financial Year 2023-24 Due to the above reasons unable to publish the Financial Results of the Company along with all other documents as per the provisions of Regulation 33 of SEBI (LODR) Regulations, 2015). The Board Meeting concluded at 5.00 P.M. (As per BSE Announcement dated on 06/09/2024)
29-Jun-2024	05-Jul-2024	Change in Auditors	VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/07/2024 inter alia to consider and approve To recommend the Appointment of Statutory Auditors to fill the Casual Vacancy Caused by Resignation The Board of Directors of the Company at its meeting held on Friday, the 05th day of July, 2024 inter alia, have approved / resolved/ taken note of the following: 1. Pursuant to the recommendation of the Audit Committee, the Board of Directors has considered and approved the appointment of M/s.SVRL & Co., Chartered Accountants, as Statutory Auditors of the Company in the casual vacancy caused by the resignation, subject to the approval of shareholders of the company. 2. To convene extra ordinary general meeting of the company to be held through Video Conferencing ('VC')/Other Audio-Visual Means ('OAVM') on Wednesday, the 14th day of August, 2024. The venue of the EGM shall be deemed to be the Registered Office of the Company. (As per BSE Announcement Dated on 05/07/2024)
08-May-2024	20-May-2024	Accounts	VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2024 inter alia to consider and approve Notice of Board Meeting / Closure of Trading Window. The Board Meeting to be held on 20/05/2024 Stands Cancelled. (As Per BSE Announcement Dated on: 17/05/2024)
31-Jan-2024	14-Feb-2024	Quarterly Results	VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 further to our letter dated 27.12.2023 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on 14th day of February 2024 at Hyderabad inter alia to consider and approve un-audited Financial Results (Standalone & Consolidated) of the company for the Quarter and nine months ended December 31 2023. Further we would like to inform that pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the company has intimated its Designated Persons including Directors regarding the closure of trading window from 01.01.2024 to till 48 hours after the declaration of un-audited Financial Results (Standalone & Consolidated) of the company for the Quarter and nine months ended December 31 2023 Results Q3FY24 (As per BSE Announcement Dated on 14/02/2024)
28-Oct-2023	14-Nov-2023	Quarterly Results	VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 further to our letter dated 30.09.2023 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday 14th Day of November 2023 at Hyderabad inter alia to consider and approve un-audited Financial Results (Standalone & Consolidated) of the company for the quarter and half year ended 30th September 2023. Further we would like to inform that pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the company has intimated its Designated Persons including Directors regarding the closure of trading window from 01.10.2023 to till 48 hours after the declaration of un-audited Financial Results (Standalone & Consolidated) of the company for the quarter and half year ended 30th September 2023. VIVIMED LABS LIMITED has informed BSE about Board Meeting to be held on 14 Nov 2023 to consider financial statements for the period ended September 2023. Financial results. Results 30.09.2023 (As Per BSE Announcement Dated on 14/11/2023)
18-Oct-2023	18-Oct-2023	AGM	The Board of Directors of the Company at its meeting held on October 18, 2023 inter alia, have approved / resolved/ taken note of the following: 1. Directors Report for the financial year ended 31.03.2023 together with annexure thereto. 2. Convening of Annual General Meeting (AGM) on 13.11.2023 and Notice of AGM. 3. Fixed Book closure dates from Wednesday, of November 08, 2023 to Monday, of November 13, 2023 (both days inclusive) for the purpose of AGM.
28-Jul-2023	14-Aug-2023	Quarterly Results	VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve Notice of Board Meeting / Closure of Trading Window The Board of Directors of the Company at its meeting held on August 14, 2023 inter alia, have approved / resolved/ taken note of the following: 1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved the submission of the Un-audited Financial Results (Standalone & Consolidated) for the Quarter ended June 30, 2023 attached herewith; 2. Auditors's Limited Review Report on the Un-audited Financial Statements of the Company for the Quarter ended June 30, 2023. 3. To file an application to the office of the Registrar of Companies, Bangalore, Karnataka, seeking an extension of time by three months for the convening of AGM for the Financial Year 2022-23 The Board Meeting concluded at 20.30 P.M (As per BSE Announcement Dated on 14/08/2023)
18-May-2023	30-May-2023	Quarterly Results	VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 further to our letter dated 28.03.2023 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday 30th Day of May 2023 at Hyderabad inter alia to consider and approve audited Financial Results (Standalone & Consolidated) of the company for the quarter and year ended 31st March 2023. Further we would like to inform that pursuant to the SEBI (Prohibition of Insider Trading) Regulations the company has intimated its Designated Persons including Directors regarding the closure of trading window from 01.04.2023 to till 48 hours after the declaration of audited Financial Results (Standalone & Consolidated) of the company for the quarter and year ended 31st March 2023. Outcome of Board Meeting- Audited financial results for the quarter and yearended 31 March, 2023 (As Per BSE Announcement dated on 30.05.2023)
01-Feb-2023	13-Feb-2023	Quarterly Results	Quarterly Results VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements), 2015, further to our letter dated 28.12.2022, we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on Monday, 13th day of February, 2023 at Hyderabad inter alia to consider and approve, (1).un-audited Financial Results (Standalone & Consolidated) of the company for the Quarter and nine months ended December 31, 2022 and (2). AGM for FY2022, related matters. Further, we would like to inform that pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company has intimated its 'Designated Persons including Directors' regarding the closure of trading window from 01.01.2023 to till 48 hours after the declaration of un-audited Financial Results (Standalone & Consolidated) of the company for the Quarter and nine months ended December 31, 2022. The Board of Directors of the Company at its meeting held on February 13, 2023 inter alia, have approved / resolved/ taken note of the following: 1. Considered and approved the submission of the Un-audited Financial Results (Standalone & Consolidated) for the Quarter and nine months ended December 31, 2022 attached herewith; 2. Auditors's Limited Review Report on the Un-audited Financial Statements of the Company for the Quarter and nine months ended December 31, 2022. 3. Directors Report for the financial year ended 31.03.2022 together with annexure thereto. 4. Convening of Annual General Meeting (AGM) on 18.03.2023 and Notice of AGM. 5. Fixed Book closure dates from Monday, March 13, 2023 to Saturday, March 18, 2023 (both days inclusive) for the purpose of AGM. The Board Meeting concluded at 6.00 P.M. With reference to the above, the following changes/ corrections are for your information: 1. Convening of 34th Annual General Meeting (AGM) for the financial year 2022 on 27.03.2023. 2. Fixed Book closure dates from Wednesday, March 22, 2023 to Monday, March 27, 2023 (both days inclusive) for the purpose of 34th AGM. You are requested to take note of the above. (As Per BSE Announcement dated on 13.02.2023)

1 2

LOGIN HERE

Vivimed Labs Ltd

Board Meeting